Public health experts are now having their attention piqued by a new subvariant known as EG.5, which is becoming a dominant strain in the United States.
The National Institutes of Health recently announced the first two of the RECOVER initiative’s long COVID clinical trials are now underway and open for enrollment.
The first study, called RECOVER-NEURO, will investigate interventions for long COVID cognitive dysfunction by testing therapies such as transcranial direct current stimulation. The second study, RECOVER-VITAL, will target viral persistence with its first intervention testing a long regimen of the antiviral nirmatrelvir/ritonavir (Paxlovid). Two other trials, RECOVER-SLEEP and RECOVER-AUTONOMIC, will also launch soon.